Abstract
Duodenal metastasis from renal cell carcinoma (RCC), though rare, warrants consideration in patients with unexplained gastrointestinal (GI) symptoms. Endoscopic evaluation and immunohistochemistry (IHC) are essential for accurate diagnosis, while molecular profiling helps identify mutations influencing disease behavior and treatment response. Systemic therapy with targeted agents and immunotherapy requires careful monitoring due to potential toxicity. A multidisciplinary approach remains essential for optimizing management and surveillance strategies in metastatic RCC.